Meg specialises in US corporate and securities law, advising on, among other things, general corporate matters and venture capital financing transactions, particularly in the life sciences sector.
Meg's day-to-day work focuses on advising life sciences and technology companies at all stages of development, with a particular focus on advising both companies and investors in venture capital financing transactions, from early-stage to late-stage. She also works closely with entrepreneurs to counsel them through initial company formation issues, day-to-day corporate governance matters, and liquidity events.
Prior to joining Taylor Wessing, she spent ten years at a top-tier firm in California, where she represented prominent US and international companies and funds in life sciences and technology financing transactions and exits. She is a current member of the California Bar.
Meg particularly enjoys advising clients on complex US and cross-border venture financing transactions.
Represented client utilizing a generated AI discovery platform in oversubscribed financing round with multiple strategic and institutional investors
Represented U.S. medical imaging software and device company in late-stage financing round
von mehreren Autoren
Advising Artificial Societies on Pre-Seed and Seed funding rounds
von mehreren Autoren
Reporting clinical trial results to the market
von mehreren Autoren
von mehreren Autoren
von Kathleen Munstermann-Senff, LL.M. (Medizinrecht) und Dr. Martin Jäger
von mehreren Autoren
von Ulf Gosejacob und Victoria Theresa Meyer, LL.M. (Cape Town)
von mehreren Autoren
von mehreren Autoren
von Richard Faichney und Elinor Picton
von Kathleen Munstermann-Senff, LL.M. (Medizinrecht) und Dr. Lisa Rottmann, LL.M. (Medizinrecht)